Pharvaris (PHVS) News Today $17.40 -0.04 (-0.23%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 19, 2024 | uk.finance.yahoo.comPharvaris N.V. (9EN.SG)June 11, 2024 | globenewswire.comPharvaris Announces Annual Meeting of ShareholdersJune 4, 2024 | globenewswire.comPharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesMay 13, 2024 | globenewswire.comPharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesMay 10, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | markets.businessinsider.comPharvaris’s Promising Drug Candidate Deucrictibant Bolsters Buy RatingMay 9, 2024 | markets.businessinsider.comWedbush Keeps Their Buy Rating on Pharvaris (PHVS)May 9, 2024 | msn.comPHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024May 8, 2024 | globenewswire.comPharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateApril 22, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Up 8%Pharvaris (NASDAQ:PHVS) Stock Price Up 8%April 22, 2024 | marketbeat.comMorgan Stanley Reiterates "Overweight" Rating for Pharvaris (NASDAQ:PHVS)Morgan Stanley reaffirmed an "overweight" rating and issued a $34.00 target price on shares of Pharvaris in a report on Monday.April 15, 2024 | markets.businessinsider.comPharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE TreatmentApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid FinancialsApril 12, 2024 | finance.yahoo.comPharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth PlansApril 12, 2024 | investing.comPharvaris appoints new CFO to bolster financial strategyApril 11, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial StabilityApril 11, 2024 | seekingalpha.comPHVS Pharvaris N.V.April 10, 2024 | investorplace.comPHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023April 10, 2024 | globenewswire.comPharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateApril 10, 2024 | globenewswire.comPharvaris Appoints David Nassif, J.D., as Chief Financial OfficerApril 4, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceApril 3, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Shares Gap Down to $22.15Pharvaris (NASDAQ:PHVS) Shares Gap Down to $22.15March 18, 2024 | globenewswire.comPharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesMarch 6, 2024 | globenewswire.comPharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesMarch 5, 2024 | globenewswire.comPharvaris to Participate in the Leerink Global Biopharma Conference 2024February 29, 2024 | marketbeat.comPharvaris (NASDAQ:PHVS) Short Interest Down 49.0% in FebruaryPharvaris (NASDAQ:PHVS - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 15th, there was short interest totalling 108,300 shares, a decrease of 49.0% from the January 31st total of 212,300 shares. Based on an average daily volume of 162,600 shares, the short-interest ratio is presently 0.7 days. Currently, 1.1% of the shares of the company are short sold.February 26, 2024 | markets.businessinsider.comPharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE TreatmentFebruary 25, 2024 | msn.comPharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97February 22, 2024 | finance.yahoo.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 22, 2024 | globenewswire.comPositive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingFebruary 16, 2024 | finance.yahoo.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 16, 2024 | globenewswire.comPharvaris Announces Extraordinary Meeting of ShareholdersFebruary 14, 2024 | markets.businessinsider.comWedbush Reaffirms Their Buy Rating on Pharvaris (PHVS)January 26, 2024 | finance.yahoo.comPharvaris to Present at the WSAAI Annual Meeting 2024January 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris with Increased Price Target Following FDA Regulatory AdvancesJanuary 23, 2024 | finance.yahoo.comPharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE ProgramJanuary 22, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksJanuary 22, 2024 | msn.comPharvaris rises as FDA lifts hold on hereditary angioedema candidateJanuary 22, 2024 | markets.businessinsider.comPharvaris Says FDA Lifts Clinical Hold On IND For Deucrictibant For Treatment Of HAE AttacksJanuary 22, 2024 | finance.yahoo.comPharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksJanuary 17, 2024 | seekingalpha.comPharvaris: Digging Deep For Sufficient Market SizeJanuary 9, 2024 | markets.businessinsider.comPositive Clinical Trials and Strong Financial Position Support Buy Rating for PharvarisJanuary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pharvaris Amid Anticipated Clinical Updates and Positive Trial ProspectsJanuary 5, 2024 | finanznachrichten.dePharvaris N.V.: Pharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesJanuary 5, 2024 | finance.yahoo.comPharvaris Provides Business Update and Outlines 2024 Strategic PrioritiesDecember 17, 2023 | msn.comPharvaris (PHVS) Price Target Increased by 38.65% to 32.93December 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Pharvaris (PHVS) and Tourmaline Bio (TRML)December 11, 2023 | finance.yahoo.comPharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last weekDecember 8, 2023 | tmcnet.comPharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Dave Ramsey Makes Big Mistake Live On Air (Ad)Dave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW. GET THE FREE GUIDE PHVS Media Mentions By Week PHVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHVS News Sentiment▼0.630.62▲Average Medical News Sentiment PHVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHVS Articles This Week▼11▲PHVS Articles Average Week Get Pharvaris News Delivered to You Automatically Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Evelo Biosciences News Grifols News LAVA Therapeutics News Mainz Biomed News NLS Pharmaceutics News Procaps Group News Qilian International Holding Group News Eli Lilly and Company News Novo Nordisk A/S News Johnson & Johnson News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHVS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.